Shingles



Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   Seoul National University Hospital
Recruiting


Zoster Eye Disease Study


Condition:   Herpes Zoster Ophthalmicus
Interventions:   Drug: Masked Placebo;   Drug: Masked Oral Valacyclovir
Sponsors:   New York University School of Medicine;   National Eye Institute (NEI);   National Institutes of Health (NIH)
Recruiting


Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax vaccine
Sponsor:   HaEmek Medical Center, Israel
Recruiting


Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting


Optimal Timing of Zoster Vaccine After Zoster Illness


Condition:   Shingles
Intervention:   Biological: Zostavax
Sponsor:   Seoul National University Hospital
Completed



Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Completed


Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds


Conditions:   Shingles;   Herpes Zoster
Interventions:   Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
Sponsors:   University of Colorado, Denver;   GlaxoSmithKline
Active, not recruiting


Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Completed


Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK1437173A)
Sponsor:   GlaxoSmithKline
Completed


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy


Condition:   Herpes Zoster
Interventions:   Biological: GSK 1437173A;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed


Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed


Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older


Condition:   Herpes Zoster
Intervention:   Biological: Herpes zoster vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Completed


Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed


ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)


Conditions:   Herpes Zoster;   Shingles
Intervention:   Biological: ZOSTAVAX™
Sponsors:   Merck Sharp & Dohme Corp.;   Kaiser Permanente
Active, not recruiting


Herpes Zoster Vaccine for Bone Marrow Transplant Donors


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   University of Sydney
Recruiting


Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly


Condition:   Shingles
Intervention:   Biological: ZOSTAVAX
Sponsors:   Emory University;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects


Condition:   Herpes Zoster
Intervention:   Procedure: Blood sample
Sponsor:   GlaxoSmithKline
Completed


Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents


Conditions:   Immunosenescence;   Shingles
Intervention:   Biological: Varicella Zoster Virus Vaccine (Zostavax)
Sponsors:   University of Colorado, Denver;   National Institute on Aging (NIA);   Merck Sharp & Dohme Corp.
Active, not recruiting


Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed


Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor:   GlaxoSmithKline
Completed


Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine 1437173A;   Biological: Placebo vaccine (saline)
Sponsor:   GlaxoSmithKline
Completed


Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed


Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects


Conditions:   Herpes Zoster (Shingles);   Shingles
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed


Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)


Condition:   Shingles
Interventions:   Biological: zoster vaccine live (Oka/Merck);   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Refine Your Search Advanced Search